Cargando…

Progress in the Application of Drugs for the Treatment of Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause physical disorders. Although environmental factors and susceptibility genes are reported to play a role in the pathogenesis o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Weipeng, Ma, Denglei, Li, Lin, Zhang, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313804/
https://www.ncbi.nlm.nih.gov/pubmed/34326775
http://dx.doi.org/10.3389/fphar.2021.724718
_version_ 1783729418444734464
author Wei, Weipeng
Ma, Denglei
Li, Lin
Zhang, Lan
author_facet Wei, Weipeng
Ma, Denglei
Li, Lin
Zhang, Lan
author_sort Wei, Weipeng
collection PubMed
description Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause physical disorders. Although environmental factors and susceptibility genes are reported to play a role in the pathogenesis of MS, its etiology still remains unclear. At present, there is no complete cure, but there are drugs that decelerate the progression of MS. Traditional therapies are disease-modifying drugs that control disease severity. MS drugs that are currently marketed mainly aim at the immune system; however, increasing attention is being paid to the development of new treatment strategies targeting the CNS. Further, the number of neuroprotective drugs is presently undergoing clinical trials and may prove useful for the improvement of neuronal function and survival. In this review, we have summarized the recent application of drugs used in MS treatment, mainly introducing new drugs with immunomodulatory, neuroprotective, or regenerative properties and their possible treatment strategies for MS. Additionally, we have presented Food and Drug Administration-approved MS treatment drugs and their administration methods, mechanisms of action, safety, and effectiveness, thereby evaluating their treatment efficacy.
format Online
Article
Text
id pubmed-8313804
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83138042021-07-28 Progress in the Application of Drugs for the Treatment of Multiple Sclerosis Wei, Weipeng Ma, Denglei Li, Lin Zhang, Lan Front Pharmacol Pharmacology Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause physical disorders. Although environmental factors and susceptibility genes are reported to play a role in the pathogenesis of MS, its etiology still remains unclear. At present, there is no complete cure, but there are drugs that decelerate the progression of MS. Traditional therapies are disease-modifying drugs that control disease severity. MS drugs that are currently marketed mainly aim at the immune system; however, increasing attention is being paid to the development of new treatment strategies targeting the CNS. Further, the number of neuroprotective drugs is presently undergoing clinical trials and may prove useful for the improvement of neuronal function and survival. In this review, we have summarized the recent application of drugs used in MS treatment, mainly introducing new drugs with immunomodulatory, neuroprotective, or regenerative properties and their possible treatment strategies for MS. Additionally, we have presented Food and Drug Administration-approved MS treatment drugs and their administration methods, mechanisms of action, safety, and effectiveness, thereby evaluating their treatment efficacy. Frontiers Media S.A. 2021-07-13 /pmc/articles/PMC8313804/ /pubmed/34326775 http://dx.doi.org/10.3389/fphar.2021.724718 Text en Copyright © 2021 Wei, Ma, Li and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wei, Weipeng
Ma, Denglei
Li, Lin
Zhang, Lan
Progress in the Application of Drugs for the Treatment of Multiple Sclerosis
title Progress in the Application of Drugs for the Treatment of Multiple Sclerosis
title_full Progress in the Application of Drugs for the Treatment of Multiple Sclerosis
title_fullStr Progress in the Application of Drugs for the Treatment of Multiple Sclerosis
title_full_unstemmed Progress in the Application of Drugs for the Treatment of Multiple Sclerosis
title_short Progress in the Application of Drugs for the Treatment of Multiple Sclerosis
title_sort progress in the application of drugs for the treatment of multiple sclerosis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313804/
https://www.ncbi.nlm.nih.gov/pubmed/34326775
http://dx.doi.org/10.3389/fphar.2021.724718
work_keys_str_mv AT weiweipeng progressintheapplicationofdrugsforthetreatmentofmultiplesclerosis
AT madenglei progressintheapplicationofdrugsforthetreatmentofmultiplesclerosis
AT lilin progressintheapplicationofdrugsforthetreatmentofmultiplesclerosis
AT zhanglan progressintheapplicationofdrugsforthetreatmentofmultiplesclerosis